Astel­las flesh­es out more PhI­II da­ta for Claudin 18.2 drug

Just weeks af­ter un­veil­ing the first de­tailed late-stage da­ta on its CLDN18.2 drug, Astel­las is beef­ing up the da­ta pack­age with re­sults from a sec­ond …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.